Developer docs
API playgroundTry for free, no card

Search company profiles

BIOEMTECH

Full company profile

uuid0005dbm

Namestring
BIOEMTECH
Legal namestring
BioEmission Technology Solutions S.A.
Websiteurl
bioemtech.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

BIOEMTECH (legally BioEmission Technology Solutions S.A.) is a privately held Greek biotech founded in 2013 as BET Solutions and rebranded by 2017. Headquartered in Gerakas, Attica (Athens), Greece, with 11-50 employees (the company states a team of over 30 plus collaborators), it operates at the intersection of preclinical molecular imaging hardware and contract research services for the radiopharmaceutical field. It serves pharmaceutical and biotech drug developers, academic and research institutions, and nuclear medicine centers conducting radiopharmaceutical research, targeted radioligand/alpha therapy development, and molecular imaging studies.

The company's core technology is a portfolio of desktop-sized preclinical imaging scanners: β-eye (PET), γ-eye (SPECT/planar gamma), and φ-eye (optical fluorescence/bioluminescence). A central technical differentiator is the systems' ability to image alpha-emitting isotopes such as Ac-225 and Pb-212 — considered difficult or impossible on conventional preclinical systems — at clinically translational activity levels and scanning times, with simultaneous multi-animal imaging (up to four mice on the large field-of-view γ-eye). The portfolio is complemented by accessories (biomimetic mouse phantoms, vital-signs monitoring, rodent platforms), software tools, and an emerging GenAI-based tool that derives 3D dosimetry from 2D imaging data (developed under the Fortissimo Plus initiative using HPC resources from GRNET and CINECA). The φ-eye carries CE marking (2023) and the company is ISO 9001:2015 certified.

BIOEMTECH monetizes through three streams: hardware sales of its imaging systems, professional CRO services (in vitro assays, radionuclide therapy, molecular imaging, GLP toxicology, dosimetry, and disease/PDX models), and supporting software tools. Pricing is undisclosed and quote-based. Go-to-market combines direct enterprise field sales (Europe and major global accounts) with channel distributors for international markets — LabLogic (North America), Fusion Scientific Technologies (India), and Nuohai Life Science (China) — supported by scientific conferences, an annual preclinical workshop series, webinars, and content marketing. The company was substantially funded through EU research grants (Horizon 2020 projects including CUPIDO, nTrack, B2B, ERROR, VIVOIMAG) and a 2019 venture round from Metavallon VC, rather than large venture rounds.

Short descriptiontext

BIOEMTECH is a Greek biotech that builds desktop preclinical PET, SPECT, and optical imaging systems and provides CRO services for radiopharmaceutical research, serving pharma, biotech, and academic institutions developing targeted alpha and radioligand therapies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersAthens, Greece
HQ citystring
Athens
HQ countrystring
Greece
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical imaging systems, radiopharmaceutical research, molecular imaging CRO, PET SPECT scanners, targeted alpha therapy imaging
Industry3 codes
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAHABAE
Nuclear Medicine & Molecular Imaging (SPECT/PET)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
NAICS code3 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Diagnostic Imaging Centers621512
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Laboratory Analytical Instruments3826
  • Services-Medical Laboratories8071
  • Surgical & Medical Instruments & Apparatus3841
Product category
Preclinical Imaging Systems (PET/SPECT/Optical) and Radiopharmaceutical CRO Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Preclinical CRO Services
TypeProfessional Services
Description

Contract research organization services including in vitro assays, radionuclide therapy studies, molecular imaging, GLP toxicology, dosimetry, and disease models for pharmaceutical and biotech clients

bioemtech.com
2Imaging Systems
TypeHardware Sales
Description

Sale of proprietary preclinical imaging systems (β-eye, γ-eye, φ-eye) to academic institutions, pharmaceutical companies, and contract research organizations

bioemtech.com
3Software Tools
TypeSubscription Recurring
Description

Software tools for imaging analysis, dosimetry, and data processing supporting the imaging systems and CRO services

bioemtech.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1β-eye
Description

PET (Positron Emission Tomography) preclinical imaging scanner for real-time dynamic imaging of positron-emitting isotopes

bioemtech.com
+3 more records
Core offering1 text field

BIOEMTECH designs, manufactures, and sells proprietary desktop-sized preclinical molecular imaging systems (β-eye PET scanner, γ-eye SPECT/planar gamma imager, φ-eye optical imager) along with complementary accessories and software tools, while also operating as a preclinical contract research organization (CRO) offering molecular imaging, radionuclide therapy, GLP toxicology, dosimetry, disease models, and in vitro assay services for radiopharmaceutical research and drug development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Enables experiments at clinically translational activity levels and scanning times unique to preclinical imaging
+2 more records
Product overview1 text field

BIOEMTECH offers a portfolio of preclinical imaging products (β-eye™ PET scanner, γ-eye™ SPECT system, and φ-eye™ optical imager) and provides comprehensive CRO preclinical services (molecular imaging, dosimetry, GLP toxicology, radionuclide therapy, disease models). The imaging systems are desktop-sized devices designed for radiopharmaceutical research, particularly alpha-emitter imaging (Ac-225, Pb-212). The products are complemented by accessories (phantoms, vital signs monitors, rodent platforms) and software tools, enabling end-to-end preclinical research workflows.

Product and service13 records
1β-eye™ (PET Imaging System)
CategoryPreclinical Imaging System (PET)
Description

High-resolution PET (Positron Emission Tomography) imaging scanner for preclinical and translational research, providing real-time dynamic imaging with clinically translational activity levels and scanning times. Supports positron-emitting isotopes and customized configurations including in ovo imaging.

2γ-eye™ (SPECT Imaging System)
CategoryPreclinical Imaging System (SPECT)
Description

Benchtop SPECT (Single Photon Emission Computed Tomography) and planar gamma imaging system for preclinical and translational research, capable of imaging therapeutic alpha emitters (Ac-225, Pb-212) and supporting simultaneous multi-animal imaging via a large field of view configuration.

3φ-eye™ (Optical Imaging System)
CategoryPreclinical Imaging System (Optical)
Description

Optical imaging system for in vivo fluorescence and bioluminescence imaging of biomolecules labeled with chromophores, used in preclinical drug discovery and molecular imaging applications; CE-marked for clinical use.

4Mouse Phantom (Fillable Biomimetic Phantom)
CategoryImaging Accessory
Description

Fillable biomimetic mouse phantom used for imaging calibration, validation, and quality control — including use with clinical SPECT/CT cameras — supplied to institutions such as Johns Hopkins University for prototype preclinical device development.

5Vital Signs Monitoring
CategoryImaging Accessory
Description

Vital signs monitoring equipment used during preclinical imaging procedures to track animal physiology.

6Rodent Procedure Platforms
CategoryImaging Accessory
Description

Platforms for handling and positioning rodents during preclinical imaging procedures.

7Molecular Imaging CRO Services
CategoryCRO Service
Description

Contract research services combining PET, SPECT, and optical imaging modalities for preclinical drug development.

8Radionuclide Therapy CRO Services
CategoryCRO Service
Description

Contract research services for preclinical radionuclide therapy development, with imaging capabilities for therapeutic isotopes including alpha emitters.

9Dosimetry CRO Services
CategoryCRO Service
Description

Preclinical dosimetry services providing absorbed-dose estimates, pharmacokinetic insights, and radiobiological modeling for radiopharmaceutical development, supported by a GenAI-based 3D dosimetry tool.

10GLP Toxicology CRO Services
CategoryCRO Service
Description

Regulatory-compliant Good Laboratory Practice (GLP) toxicology studies for preclinical drug development.

11In Vitro Assays & Stem Cell Therapy CRO Services
CategoryCRO Service
Description

Contract research services for in vitro assays and stem cell therapy studies supporting preclinical drug development.

12Disease Models CRO Services
CategoryCRO Service
Description

Preclinical disease model development and validation services for oncology and radiopharmaceutical research, including PDX models (e.g., via CERTIS Oncology partnership).

13Software Tools
CategorySoftware Product
Description

Subscription software tools for image analysis, data processing, dosimetry, and research support, including a GenAI-based 3D dosimetry module and the Pose2Xray synthetic X-ray image generator.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-05-22
Description

Strategic partnership focused on expanding sales and support for BIOEMTECH's innovative preclinical imaging solutions throughout North America. LabLogic provides dedicated sales and service support for BIOEMTECH's portfolio including β-eye, γ-eye and φ-eye systems, ensuring comprehensive local support and responsive service.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-07
Description

Strategic collaboration to offer integrated patient-derived xenograft (PDX) access for radiopharmaceutical preclinical studies. CERTIS supplies study-ready PDX avatars representing diverse tumor types for functional testing within BIOEMTECH's preclinical PET/SPECT imaging workflows, enabling sponsors to evaluate targeted radiotherapeutics with higher translational relevance.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-17
Description

Strategic supply agreement to ensure reliable supply of Actinium-225 (Ac-225) for preclinical radiopharmaceutical research. Agreement provides consistent access to Ac-225 starting Q1 2026, supporting preclinical studies and accelerating radiopharmaceutical development for BIOEMTECH's customers.

Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2017-11-13
Description

Agreement for provision of Hamamatsu state-of-the-art optical sensors for integration into BIOEMTECH imaging systems.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2017-11-06
Description

Official distribution agreement for distributing preclinical molecular imaging systems (β-eye, γ-eye, φ-eye) to the growing Indian market.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2017-10-05
Description

Distribution partnership for preclinical molecular imaging systems to the emerging Chinese market.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Collaboration within smartHEALTH project resulting in development and validation of pediatric radiation dosing software and enhancement of φ-eye preclinical imaging system with multi-angle imaging capabilities and improved data analysis tools.

Strategic tierSupportingTypeTechnology or Integration
Description

Collaboration at 1st BIOEMTECH User Meeting where Jacob Hestermann from Ratio Therapeutics presented on 225Ac in vivo imaging, demonstrating how γ-eye enables capture of RadioLigand Therapy dynamics in real time.

Strategic tierSupportingTypeTechnology or Integration
Description

Partnership under Fortissimo Plus initiative for GenAI-based 3D dosimetry project, utilizing HPC resources from GRNET for enhanced dosimetry accuracy in preclinical research.

Strategic tierSupportingTypeTechnology or Integration
Description

Partnership under Fortissimo Plus initiative for GenAI-based tool for 3D dosimetry from 2D imaging in preclinical studies.

11CINECA
Strategic tierSupportingTypeTechnology or Integration
Description

Utilizing HPC resources from CINECA center for the GenAI-based 3D dosimetry project for preclinical studies.

bioemtech.com
Strategic tierSupportingTypeTechnology or Integration
Description

Collaboration providing innovative phantom technology for BIOEMTECH workshops. Phantech supplied mouse restrainers and BioMouse fillable biomimetic mouse phantoms for animal preparation sessions.

13NuclearPharm
Strategic tierSupportingTypeTechnology or Integration
Description

Collaboration with Antonio Shegani, CEO of NuclearPharm and research associate at NCSR DEMOKRITOS, demonstrating high-resolution in vivo PET tomography with β-eye.

bioemtech.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Bruker is a leading life-science instrumentation company offering preclinical PET, SPECT, MRI and optical imaging systems through its Bruker BioSpin / Molecular Imaging division. It is the most established commercial competitor in preclinical nuclear imaging and operates across far broader applications than BIOEMTECH's radiopharmaceutical focus.

TypeBroad incumbent
Description

Revvity operates the PerkinElmer legacy life-sciences franchise, including IVIS optical imaging and a broad preclinical imaging portfolio. It competes in fluorescence/bioluminescence and PET/SPECT preclinical imaging and has a much larger global sales and service footprint than BIOEMTECH.

TypeDirect peer
Description

Mediso is a Hungarian manufacturer of preclinical PET, SPECT, CT and multimodal imaging systems (nanoScan, AnyScan). It is one of the closest direct competitors to BIOEMTECH's β-eye and γ-eye in preclinical nuclear medicine imaging.

TypeDirect peer
Description

Molecubes is a Belgian vendor of benchtop preclinical PET, SPECT and CT systems (β-CUBE, γ-CUBE, X-CUBE). It directly competes with BIOEMTECH in the desktop/cube-format preclinical imaging category and targets similar academic and CRO customers.

TypeBroad incumbent
Description

Siemens Healthineers sells preclinical and clinical PET/SPECT/CT systems (e.g., Inveon legacy line) and is a broad incumbent in nuclear medicine imaging. While its primary focus is clinical, its preclinical instruments overlap with BIOEMTECH's β-eye/γ-eye at larger academic and pharma customers.

TypeBroad incumbent
Description

Charles River is a global preclinical CRO offering safety assessment, discovery and radiolabeled services. It competes with BIOEMTECH's CRO services in molecular imaging, dosimetry and GLP toxicology for radiopharmaceutical and general drug-development sponsors, though at much larger scale and scope.

TypeDirect peer
Description

Invicro provides preclinical and clinical imaging CRO services, including PET and radiopharmaceutical analysis. It is a direct competitor to BIOEMTECH's molecular imaging and dosimetry CRO services for pharma/biotech sponsors.

TypeOthers
Description

LabLogic is a UK-based vendor of radiodetection, chromatography and QC instruments for life-science and nuclear-medicine labs. It is now BIOEMTECH's North American distribution partner, but its broader PET/SPECT radio-TLC and dose-calibrator portfolio overlaps with end-customers BIOEMTECH serves and makes it both a channel and an adjacent technology peer.

TypeOthers
Description

CERTIS Oncology provides patient-derived xenograft (PDX) and tumor model services for oncology drug development. It is a strategic partner of BIOEMTECH for PDX-based radiopharmaceutical studies, but its disease-model offerings also compete with BIOEMTECH's own CRO disease-model service line.

TypeOthers
Description

NorthStar is a US radioisotope producer expanding into therapeutic isotopes including Actinium-225. It is a strategic Ac-225 supply partner to BIOEMTECH, but its broader isotope-production business shapes the supply ecosystem that BIOEMTECH's α-eye value proposition depends on.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BIOEMTECH

Preclinical Imaging Systems (PET/SPECT/Optical) and Radiopharmaceutical CRO Servicesbioemtech.com

BIOEMTECH is a Greek biotech that builds desktop preclinical PET, SPECT, and optical imaging systems and provides CRO services for radiopharmaceutical research, serving pharma, biotech, and academic institutions developing targeted alpha and radioligand therapies.

What BIOEMTECH does

BIOEMTECH (legally BioEmission Technology Solutions S.A.) is a privately held Greek biotech founded in 2013 as BET Solutions and rebranded by 2017. Headquartered in Gerakas, Attica (Athens), Greece, with 11-50 employees (the company states a team of over 30 plus collaborators), it operates at the intersection of preclinical molecular imaging hardware and contract research services for the radiopharmaceutical field. It serves pharmaceutical and biotech drug developers, academic and research institutions, and nuclear medicine centers conducting radiopharmaceutical research, targeted radioligand/alpha therapy development, and molecular imaging studies.

The company's core technology is a portfolio of desktop-sized preclinical imaging scanners: β-eye (PET), γ-eye (SPECT/planar gamma), and φ-eye (optical fluorescence/bioluminescence). A central technical differentiator is the systems' ability to image alpha-emitting isotopes such as Ac-225 and Pb-212 — considered difficult or impossible on conventional preclinical systems — at clinically translational activity levels and scanning times, with simultaneous multi-animal imaging (up to four mice on the large field-of-view γ-eye). The portfolio is complemented by accessories (biomimetic mouse phantoms, vital-signs monitoring, rodent platforms), software tools, and an emerging GenAI-based tool that derives 3D dosimetry from 2D imaging data (developed under the Fortissimo Plus initiative using HPC resources from GRNET and CINECA). The φ-eye carries CE marking (2023) and the company is ISO 9001:2015 certified.

BIOEMTECH monetizes through three streams: hardware sales of its imaging systems, professional CRO services (in vitro assays, radionuclide therapy, molecular imaging, GLP toxicology, dosimetry, and disease/PDX models), and supporting software tools. Pricing is undisclosed and quote-based. Go-to-market combines direct enterprise field sales (Europe and major global accounts) with channel distributors for international markets — LabLogic (North America), Fusion Scientific Technologies (India), and Nuohai Life Science (China) — supported by scientific conferences, an annual preclinical workshop series, webinars, and content marketing. The company was substantially funded through EU research grants (Horizon 2020 projects including CUPIDO, nTrack, B2B, ERROR, VIVOIMAG) and a 2019 venture round from Metavallon VC, rather than large venture rounds.

BIOEMTECH firmographics

Firmographics
Name
BIOEMTECH
Legal name
BioEmission Technology Solutions S.A.
Website
https://bioemtech.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
51–100 employees
Short description
BIOEMTECH is a Greek biotech that builds desktop preclinical PET, SPECT, and optical imaging systems and provides CRO services for radiopharmaceutical research, serving pharma, biotech, and academic institutions developing targeted alpha and radioligand therapies.
Ownership category
akta.pro rank

BIOEMTECH industry classification

Industry
Product category
Preclinical Imaging Systems (PET/SPECT/Optical) and Radiopharmaceutical CRO Services
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Diagnostic Imaging Centers (621512), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Laboratory Analytical Instruments (3826), Services-Medical Laboratories (8071), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAHABAE
Nuclear Medicine & Molecular Imaging (SPECT/PET)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)

Keywords

  • Preclinical imaging systems
  • Radiopharmaceutical research
  • Molecular imaging CRO
  • PET SPECT scanners
  • Targeted alpha therapy imaging

Where BIOEMTECH is headquartered

Location

Headquarters

HQ city
Athens
HQ country
Greece
HQ region
Europe

Offices1 record

Markets served

BIOEMTECH business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Preclinical CRO Services: Contract research organization services including in vitro assays, radionuclide therapy studies, molecular imaging, GLP toxicology, dosimetry, and disease models for pharmaceutical and biotech clients
  2. Imaging Systems: Sale of proprietary preclinical imaging systems (β-eye, γ-eye, φ-eye) to academic institutions, pharmaceutical companies, and contract research organizations
  3. Software Tools: Software tools for imaging analysis, dosimetry, and data processing supporting the imaging systems and CRO services

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

BIOEMTECH product offering

Product offering

Core offering

BIOEMTECH designs, manufactures, and sells proprietary desktop-sized preclinical molecular imaging systems (β-eye PET scanner, γ-eye SPECT/planar gamma imager, φ-eye optical imager) along with complementary accessories and software tools, while also operating as a preclinical contract research organization (CRO) offering molecular imaging, radionuclide therapy, GLP toxicology, dosimetry, disease models, and in vitro assay services for radiopharmaceutical research and drug development.

Product overview

BIOEMTECH offers a portfolio of preclinical imaging products (β-eye™ PET scanner, γ-eye™ SPECT system, and φ-eye™ optical imager) and provides comprehensive CRO preclinical services (molecular imaging, dosimetry, GLP toxicology, radionuclide therapy, disease models). The imaging systems are desktop-sized devices designed for radiopharmaceutical research, particularly alpha-emitter imaging (Ac-225, Pb-212). The products are complemented by accessories (phantoms, vital signs monitors, rodent platforms) and software tools, enabling end-to-end preclinical research workflows.

Differentiator

Problem solved

Functional benefit

Brands

  • β-eye: PET (Positron Emission Tomography) preclinical imaging scanner for real-time dynamic imaging of positron-emitting isotopes
  • γ-eye
  • φ-eye
  • smartHEALTH

Products and services

  • β-eye™ (PET Imaging System) High-resolution PET (Positron Emission Tomography) imaging scanner for preclinical and translational research, providing real-time dynamic imaging with clinically translational activity levels and scanning times. Supports positron-emitting isotopes and customized configurations including in ovo imaging.
  • γ-eye™ (SPECT Imaging System) Benchtop SPECT (Single Photon Emission Computed Tomography) and planar gamma imaging system for preclinical and translational research, capable of imaging therapeutic alpha emitters (Ac-225, Pb-212) and supporting simultaneous multi-animal imaging via a large field of view configuration.
  • φ-eye™ (Optical Imaging System) Optical imaging system for in vivo fluorescence and bioluminescence imaging of biomolecules labeled with chromophores, used in preclinical drug discovery and molecular imaging applications; CE-marked for clinical use.
  • Mouse Phantom (Fillable Biomimetic Phantom) Fillable biomimetic mouse phantom used for imaging calibration, validation, and quality control — including use with clinical SPECT/CT cameras — supplied to institutions such as Johns Hopkins University for prototype preclinical device development.
  • Vital Signs Monitoring Vital signs monitoring equipment used during preclinical imaging procedures to track animal physiology.
  • Rodent Procedure Platforms Platforms for handling and positioning rodents during preclinical imaging procedures.
  • Molecular Imaging CRO Services Contract research services combining PET, SPECT, and optical imaging modalities for preclinical drug development.
  • Radionuclide Therapy CRO Services Contract research services for preclinical radionuclide therapy development, with imaging capabilities for therapeutic isotopes including alpha emitters.
  • Dosimetry CRO Services Preclinical dosimetry services providing absorbed-dose estimates, pharmacokinetic insights, and radiobiological modeling for radiopharmaceutical development, supported by a GenAI-based 3D dosimetry tool.
  • GLP Toxicology CRO Services Regulatory-compliant Good Laboratory Practice (GLP) toxicology studies for preclinical drug development.
  • In Vitro Assays & Stem Cell Therapy CRO Services Contract research services for in vitro assays and stem cell therapy studies supporting preclinical drug development.
  • Disease Models CRO Services Preclinical disease model development and validation services for oncology and radiopharmaceutical research, including PDX models (e.g., via CERTIS Oncology partnership).
  • Software Tools Subscription software tools for image analysis, data processing, dosimetry, and research support, including a GenAI-based 3D dosimetry module and the Pose2Xray synthetic X-ray image generator.

Quantifiable outcome

  • Enables experiments at clinically translational activity levels and scanning times unique to preclinical imaging
  • +2 more outcomes

Companies that use BIOEMTECH

Customer profile

Named customers9 records

Segments3 records

Ideal customer profiles2 records

BIOEMTECH technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

BIOEMTECH partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered core and supporting.

  • LabLogiccoreChannel Partner/ Reseller/ Distributor · 22 May 2026Strategic partnership focused on expanding sales and support for BIOEMTECH's innovative preclinical imaging solutions throughout North America. LabLogic provides dedicated sales and service support for BIOEMTECH's portfolio including β-eye, γ-eye and φ-eye systems, ensuring comprehensive local support and responsive service.
  • CERTIS OncologycoreStrategic or Co-development Partner · 7 May 2026Strategic collaboration to offer integrated patient-derived xenograft (PDX) access for radiopharmaceutical preclinical studies. CERTIS supplies study-ready PDX avatars representing diverse tumor types for functional testing within BIOEMTECH's preclinical PET/SPECT imaging workflows, enabling sponsors to evaluate targeted radiotherapeutics with higher translational relevance.
  • NorthStar Medical RadioisotopescoreStrategic or Co-development Partner · 17 February 2026Strategic supply agreement to ensure reliable supply of Actinium-225 (Ac-225) for preclinical radiopharmaceutical research. Agreement provides consistent access to Ac-225 starting Q1 2026, supporting preclinical studies and accelerating radiopharmaceutical development for BIOEMTECH's customers.
  • Hamamatsu Photonics K.K.supportingTechnology or Integration · 13 November 2017Agreement for provision of Hamamatsu state-of-the-art optical sensors for integration into BIOEMTECH imaging systems.
  • Fusion Scientific Technologies Pvt. Ltd.coreChannel Partner/ Reseller/ Distributor · 6 November 2017Official distribution agreement for distributing preclinical molecular imaging systems (β-eye, γ-eye, φ-eye) to the growing Indian market.
  • Nuohai Life Science Co., LtdcoreChannel Partner/ Reseller/ Distributor · 5 October 2017Distribution partnership for preclinical molecular imaging systems to the emerging Chinese market.
  • Foundation for Research and Technology – Hellas (FORTH)supportingStrategic or Co-development PartnerCollaboration within smartHEALTH project resulting in development and validation of pediatric radiation dosing software and enhancement of φ-eye preclinical imaging system with multi-angle imaging capabilities and improved data analysis tools.
  • Ratio TherapeuticssupportingTechnology or IntegrationCollaboration at 1st BIOEMTECH User Meeting where Jacob Hestermann from Ratio Therapeutics presented on 225Ac in vivo imaging, demonstrating how γ-eye enables capture of RadioLigand Therapy dynamics in real time.
  • GRNET – Greek Research & Technology NetworksupportingTechnology or IntegrationPartnership under Fortissimo Plus initiative for GenAI-based 3D dosimetry project, utilizing HPC resources from GRNET for enhanced dosimetry accuracy in preclinical research.
  • AlethiasupportingTechnology or IntegrationPartnership under Fortissimo Plus initiative for GenAI-based tool for 3D dosimetry from 2D imaging in preclinical studies.
  • CINECAsupportingTechnology or IntegrationUtilizing HPC resources from CINECA center for the GenAI-based 3D dosimetry project for preclinical studies.
  • Phantech LLCsupportingTechnology or IntegrationCollaboration providing innovative phantom technology for BIOEMTECH workshops. Phantech supplied mouse restrainers and BioMouse fillable biomimetic mouse phantoms for animal preparation sessions.
  • NuclearPharmsupportingTechnology or IntegrationCollaboration with Antonio Shegani, CEO of NuclearPharm and research associate at NCSR DEMOKRITOS, demonstrating high-resolution in vivo PET tomography with β-eye.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

BIOEMTECH competitors and assessment

Company assessment

Broad incumbents

  • Bruker Corporation: Bruker is a leading life-science instrumentation company offering preclinical PET, SPECT, MRI and optical imaging systems through its Bruker BioSpin / Molecular Imaging division. It is the most established commercial competitor in preclinical nuclear imaging and operates across far broader applications than BIOEMTECH's radiopharmaceutical focus.
  • Revvity (formerly PerkinElmer Life Sciences): Revvity operates the PerkinElmer legacy life-sciences franchise, including IVIS optical imaging and a broad preclinical imaging portfolio. It competes in fluorescence/bioluminescence and PET/SPECT preclinical imaging and has a much larger global sales and service footprint than BIOEMTECH.
  • Siemens Healthineers (preclinical / Molecular Imaging): Siemens Healthineers sells preclinical and clinical PET/SPECT/CT systems (e.g., Inveon legacy line) and is a broad incumbent in nuclear medicine imaging. While its primary focus is clinical, its preclinical instruments overlap with BIOEMTECH's β-eye/γ-eye at larger academic and pharma customers.
  • Charles River Laboratories: Charles River is a global preclinical CRO offering safety assessment, discovery and radiolabeled services. It competes with BIOEMTECH's CRO services in molecular imaging, dosimetry and GLP toxicology for radiopharmaceutical and general drug-development sponsors, though at much larger scale and scope.

Direct peers

  • Mediso Medical Imaging Systems: Mediso is a Hungarian manufacturer of preclinical PET, SPECT, CT and multimodal imaging systems (nanoScan, AnyScan). It is one of the closest direct competitors to BIOEMTECH's β-eye and γ-eye in preclinical nuclear medicine imaging.
  • Molecubes: Molecubes is a Belgian vendor of benchtop preclinical PET, SPECT and CT systems (β-CUBE, γ-CUBE, X-CUBE). It directly competes with BIOEMTECH in the desktop/cube-format preclinical imaging category and targets similar academic and CRO customers.
  • Invicro (a Konica Minolta company): Invicro provides preclinical and clinical imaging CRO services, including PET and radiopharmaceutical analysis. It is a direct competitor to BIOEMTECH's molecular imaging and dosimetry CRO services for pharma/biotech sponsors.

Others

  • LabLogic Systems: LabLogic is a UK-based vendor of radiodetection, chromatography and QC instruments for life-science and nuclear-medicine labs. It is now BIOEMTECH's North American distribution partner, but its broader PET/SPECT radio-TLC and dose-calibrator portfolio overlaps with end-customers BIOEMTECH serves and makes it both a channel and an adjacent technology peer.
  • CERTIS Oncology Solutions: CERTIS Oncology provides patient-derived xenograft (PDX) and tumor model services for oncology drug development. It is a strategic partner of BIOEMTECH for PDX-based radiopharmaceutical studies, but its disease-model offerings also compete with BIOEMTECH's own CRO disease-model service line.
  • NorthStar Medical Radioisotopes: NorthStar is a US radioisotope producer expanding into therapeutic isotopes including Actinium-225. It is a strategic Ac-225 supply partner to BIOEMTECH, but its broader isotope-production business shapes the supply ecosystem that BIOEMTECH's α-eye value proposition depends on.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

BIOEMTECH social profiles

Digital presence

BIOEMTECH compliance and trust

Trust signal

Compliance1 record

BIOEMTECH financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BIOEMTECH leadership team

Management profile

Number of profiles

Profiles8 records

BIOEMTECH funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BIOEMTECH M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BIOEMTECH

What does BIOEMTECH do?

BIOEMTECH designs, manufactures, and sells proprietary desktop-sized preclinical molecular imaging systems (β-eye PET scanner, γ-eye SPECT/planar gamma imager, φ-eye optical imager) along with complementary accessories and software tools, while also operating as a preclinical contract research organization (CRO) offering molecular imaging, radionuclide therapy, GLP toxicology, dosimetry, disease models, and in vitro assay services for radiopharmaceutical research and drug development.

Is BIOEMTECH a public or private company?

BIOEMTECH is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was BIOEMTECH founded?

BIOEMTECH was founded in 2013. It employs 51 to 100 people.

Where is BIOEMTECH based?

BIOEMTECH is headquartered in Athens, Greece, in the Europe region.

How does BIOEMTECH make money?

Three revenue lines are on record. Preclinical CRO Services are the primary driver. The others are imaging Systems and software Tools.

Who are BIOEMTECH's main competitors?

Broad incumbents on record are Bruker Corporation, Revvity (formerly PerkinElmer Life Sciences), Siemens Healthineers (preclinical / Molecular Imaging) and Charles River Laboratories. Direct peers are Mediso Medical Imaging Systems, Molecubes and Invicro (a Konica Minolta company). Others are LabLogic Systems, CERTIS Oncology Solutions and NorthStar Medical Radioisotopes.

Does BIOEMTECH have an API?

No public API is recorded for BIOEMTECH.

What industry is BIOEMTECH in?

BIOEMTECH's product category is Preclinical Imaging Systems (PET/SPECT/Optical) and Radiopharmaceutical CRO Services. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAHABAE, Nuclear Medicine & Molecular Imaging (SPECT/PET). Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ContractpharmaBIOEMTECH, NorthStar Medical Radioisotopes Reach Agreement for Ac-225 SupplyBIOEMTECH, an Athens-based contract research organization, has signed a strategic agreement with NorthStar Medical Radioisotopes to supply actinium-225 (Ac-225) for preclinical studies. The agreement ensures BIOEMTECH's customers will have consistent access to the alpha-emitting isotope, which is critical for developing targeted radiotherapeutics. Initial deliveries are scheduled to begin by the end of Q1 2026, with NorthStar providing isotope-specific documentation and handling guidance thereafter.MadisonstartupsNorthStar, BIOEMTECH Enter into Supply Agreement - Startup and Tech News - Madison StartupsNorthStar Medical Radioisotopes has entered into a strategic supply agreement with BIOEMTECH, a developer of high-resolution PET and SPECT imaging systems for preclinical and translational research. Under the agreement, BIOEMTECH's customers will gain access to AC-225 (Actinium-225) with the stated goal of accelerating preclinical radiopharmaceutical development. The financial terms of the agreement were not disclosed.BioSpaceBIOEMTECH and NorthStar Medical Radioisotopes Announce Strategic Supply Agreement for Actinium-225 to Support Preclinical Radiopharmaceutical ResearchBIOEMTECH announced a strategic supply agreement with NorthStar Medical Radioisotopes to secure Actinium-225 (Ac-225) for preclinical radiopharmaceutical research, with initial deliveries expected to start in Q1 2026. The agreement aims to provide a reliable supply of high-quality isotope to accelerate the development of targeted radiotherapeutics. The collaboration is designed to improve access and support for the preclinical research community.